VOOPOO
23.6.2022 18:40:06 CEST | Business Wire | Press release
VOOPOO,a global leading electronic atomization brand, released a seven-day countdown on its official website on June 23rd. According to this, a new product launch themed "More than Infinite" will be held at 10:00 p.m.(GMT+8) on June 29. As the initial new VOOPOO product launch of this year, what will be delivered in the launch is conspicuous.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005539/en/
What stories will be shared in this 8th
Anniversary Show?
The launch event is not only held for new products, but also for celebrating the 8th
establishment anniversary of VOOPOO. Since its establishment, VOOPOO has gained a reputation of developing a variety of revolutionary products. While promoting the development of the industry, VOOPOO achieved leaps of market share year by year. By far, VOOPOO has become a TOP brand in the Open Pod System. VOOPOO has also won a number of Vapoouround 2022 awards
recently, which are known as the Oscars of the atomization industry, and has been highly praised by the industry and users. There is no doubt that VOOPOO will reveal some behind-brand stories at this 8th
anniversary.
Is there a strong association between the Infinity symbol and VOOPOO brand?
The posters released on the official website and social platforms all used the infinity symbol as the main visual element of the launch.VOOPOO has lately launched a number of high-profile events around the world, whether the “Spark Your Life Infinite Challenge ”on the Tik-Tok, or the pop-up events
organized by graffiti artists in the United Kingdom and Indonesia, were all attached to the infinity symbol strongly. Now it is clear that those were organized to warming up the launch. This launch themed as “More than infinity
”, emphasizing that the infinity symbol seems to become the cultural totem of the VOOPOO brand. As for which brand spirit the infinity symbol marks, it will only be revealed on the launch.
What revolutionary breakthroughs will the new products be making in this launch?
Another highlight of the launch is the new products VOOPOO will debut this time. Judging from the relevant content disclosed on the official website, the overall KEY VISION style is very technologically avant-garde, and several products will be released at the same time. For VOOPOO, which was known for its product innovation
, the new products of this time may make various breakthroughs in design and technology as well. The official revealed that the launch will be broadcasting live on its official YouTube channel at 10:00 p.m.(GMT+8) on June 29. At that time, global vape fans and industry observers will witness and participate in this feast served by VOOPOO.
About VOOPOO
VOOPOO is a leading brand of open pod system and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. VOOPOO focuses on building two core technology platforms [Chip] and [Atomization]. VOOPOO has creatively developed GENE.AI, GENE.TT and other chips. In addition, VOOPOO independently developed three Atomization Platforms, which are TPP,PNP,ITO, aiming at differentiated users. VOOPOO has four major product series - ARGUS, DRAG, VINCI, and V-series(Doric). VOOPOO will continue to develop more national markets in the future, aiming to build one of the most influential global brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005539/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
